Lessons from Landmark trials with PCSK9i

Episodes 1-4 of 4

• 

  RestartResume

  Identifying patients for PCSK9 therapy

  RestartResume

  Identifying patients for PCSK9 therapy

  Lessons from Landmark trials with PCSK9i

  Identifying patients for PCSK9 therapy

  • 

    

    Kees Hovingh, MD

• 

  RestartResume

  Guidelines and the role of non-statin therapies for high risk ASCVD patients

  RestartResume

  Guidelines and the role of non-statin therapies for high risk ASCVD patients

  Lessons from Landmark trials with PCSK9i

  Guidelines and the role of non-statin therapies for high risk ASCVD patients

  • 

    

    Wouter Jukema, MD

• 

  RestartResume

  Landmark trials with PCSK9 inhibitors

  RestartResume

  Landmark trials with PCSK9 inhibitors

  Lessons from Landmark trials with PCSK9i

  Landmark trials with PCSK9 inhibitors

  • 

    

    Ph. Gabriel Steg, MD

• 

  RestartResume

  PCSK9 inhibitors: How do they work?

  RestartResume

  PCSK9 inhibitors: How do they work?

  Lessons from Landmark trials with PCSK9i

  PCSK9 inhibitors: How do they work?